Alvotech stock surges on FDA review of Entyvio biosimilar

This is a regulatory de-risking event more than a near-term revenue inflection. For biosimilars, the market usually underestimates how much interchangeability shifts adoption from a physician-led conversion story to a pharmacy-channel distribution story, which can materially shorten the sales cycle once launched. That means the move is less about today’s filing and more about improving the probability-weighted path to share capture in a crowded, price-sensitive category.

The first-order winner is ALVOW, but the bigger second-order effect is on incumbents and adjacent biosimilar developers: if this program advances, it validates Alvotech’s execution capability and should compress the perceived regulatory discount on its pipeline. Competitors pursuing similar GI immunology biosimilars may see modest pressure on expected pricing and formulary leverage, because interchangeable status strengthens the “good enough plus easier substitution” proposition that payers like.

The key risk is timing. FDA acceptance is not approval, and the market often front-loads value on milestone headlines only to fade the name if review drags or if any comparability issues emerge later. Over the next 3–6 months, the stock is likely to trade on binary regulatory cadence rather than fundamentals; over 12–24 months, the real driver is whether interchangeability translates into actual substitution rates, which is a much harder commercialization test than getting the label.

The contrarian view is that the rally may be underpriced if investors are still thinking in traditional biosimilar terms. If interchangeability is ultimately granted, the upside is not just incremental volume but a distribution advantage that can create faster uptake than the street models for a first mover in a high-prescription chronic disease category. That makes the risk/reward asymmetrically better if one is willing to hold through headline volatility and clinical/regulatory noise.